3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
29
Phase 2
9
Phase 1/2
7
Phase NA
3
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
73
Carcinoma, Hepatocellular
67
Stomach Neoplasms
52
Pancreatic Neoplasms
40
Rectal Neoplasms
30
Colonic Neoplasms
30
Neoplasms
21
Liver Neoplasms
20
Esophageal Neoplasms
19
Neoplasm Metastasis
16
Cholangiocarcinoma
16
Esophageal Squamous Cell Carcinoma
14
Gallbladder Neoplasms
12
Biliary Tract Neoplasms
12
Lung Neoplasms
10
Gastrointestinal Neoplasms
7
Adenocarcinoma Of Esophagus
7
Ovarian Neoplasms
6
Prostatic Neoplasms
5
Neoplasms by Site
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Polyps
4
Neoplasms by Histologic Type
4
Melanoma
4
Hematologic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Adenoma
4
Recurrence
3
Interventions
pertuzumab
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Salivary Gland Neoplasms
×
Gastrointestinal
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled